Bayer nabs FDA approval for topical heartworm drug; BI sells veterinary manufacturing plant to Argenta; CWD found in captive Texas deer;

> The FDA approved Bayer's Coraxis, a topical treatment for the prevention of heartworm and the treatment of hookworms, roundworms, and whipworms. Document (PDF)

> New Zealand's Argenta acquired a manufacturing facility from Boehringer Ingelheim Vetmedica that's located in Fort Dodge, IA. Release

> A two-year-old white-tailed deer at a captive breeding facility in Medina County, TX, was diagnosed with Chronic Wasting Disease (CWD), prompting an investigation into the risk of CWD among free-ranging and captive deer and elk in the area. Article

> VaxLiant won approval from the USDA for three new adjuvants for use in poultry vaccines. Release

> Scientists at University of Pittsburgh Center for Vaccine Research received $4 million in federal grants to study a group of mosquito-borne illnesses, including eastern equine encephalitis virus (EEEV), which can be transmitted to both horses and people. Release

> Australia's Anatara Lifesciences raised $7 million in capital to develop Detach, its lead compound to prevent diarrhea in pigs and other livestock. Release (PDF)

> An international research team led by the University of Virginia School of Medicine received $1.35 million from the Human Frontier Science Program Organization to study how avian flu passes from birds to humans. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…